Denali Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $17,778 | $3,604 | $0 | $0 |
Gross Profit | 17,586 | 3,511 | -2,845 | -2,866 |
EBITDA | 73,701 | -124,900 | -125,602 | -124,665 |
EBIT | 70,126 | -127,553 | -128,447 | -128,447 |
Net Income | 70,126 | -127,553 | -128,447 | -128,549 |
Net Change In Cash | 17,778 | 3,604 | 0 | 0 |
Free Cash Flow | -118,453 | -97,807 | -133,670 | -100,062 |
Cash | 102,870 | 201,530 | 387,626 | 205,326 |
Basic Shares | 192,077 | 187,314 | 186,636 | 175,458 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $330,531 | $108,463 |
Gross Profit | -11,183 | -7,795 | 330,531 | 108,463 |
EBITDA | -497,626 | -492,886 | -128,468 | -315,587 |
EBIT | -512,438 | -501,878 | -145,194 | -325,970 |
Net Income | -512,540 | -422,773 | -145,224 | -325,991 |
Net Change In Cash | 0 | 0 | 330,531 | 108,463 |
Free Cash Flow | -422,102 | -363,606 | -370,930 | -262,549 |
Cash | 205,326 | 174,960 | 127,106 | 218,044 |
Basic Shares | 175,458 | 164,473 | 137,370 | 125,530 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.64 |
2026-06-30 | -$0.68 |
2026-03-31 | -$0.69 |
2025-12-31 | -$0.73 |